Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Anti cd3"'
Autor:
Giuseppe d'Annunzio, Andrea Scaramuzza, Sonia Toni, F. Citriniti, Salvatore Guercio Nuzio, Riccardo Bonfanti, Giulio Frontino
Publikováno v:
Minerva Pediatrics. 73
T1D (T1D) is one of the most frequent chronic disease in children and is associated to the risk of severe acute and chronic complications. There are about 550,000 children with T1D in the world; and about 86,000 children are diagnosed with T1D every
Autor:
Elie Dolgin
Publikováno v:
Nature Biotechnology. 37:1099-1101
No drug has ever delayed islet cell destruction. Now that teplizumab has, the challenge turns to identifying eligible recipients for the treatment. No drug has ever delayed islet cell destruction. Now that teplizumab has, the challenge turns to ident
Autor:
George D. Yancopoulos, David Sternberg, Gavin Thurston, S. M. Ansell, Julio C. Chavez, Israel Lowy, R. Advani, Johannes Duell, Susan O'Brien, Melanie Ufkin, Nathalie Fiaschi, Min Zhu, Jingjin Li, Vladimir Jankovic, Sara Hamon, Peter Gasparini, Robert Charnas, Jon E. Arnason, Srikanth R. Ambati, Jennifer R. Brown, Rajat Bannerji, Wen Zhang, Max S. Topp, Lieve Adriaens, A.J. Murphy, Andreas Rosenwald, John N. Allan
Publikováno v:
Hematological Oncology. 37:90-92
Autor:
Tycel Phillips, Craig A. Portell, Asher Chanan-Khan, Guillaume Cartron, William G. Wierda, Krish Patel, Hervé Ghesquières, Hervé Tilly, Kamal Bouabdallah, Chelsea M. Johnson, Raman Garcha, Gabriel Brisou, Vincent Ribrag, Jean-Marie Michot, Melhem Solh, David Liebowitz, Patricia McGovern, John C. Byrd
Publikováno v:
Blood. 138:2494-2494
Introduction: Plamotamab (XmAb13676) is a humanized bispecific antibody that binds both CD20 and CD3 to recruit cytotoxic T cells to kill CD20 expressing malignant cells. Interim results of an ongoing first-in-human (FIH), dose-escalation study (XmAb
Autor:
Elizabeth Budde, Catherine Diefenbach, Iris Sison, Ian W. Flinn, Philippe Armand, Genevive Hernandez, Ajay K. Gopal, Ibrahim Qazi, Loretta J. Nastoupil, Maya Leabman, Matthew J. Matasar, Won Seog Kim, Gareth P. Gregory, Bruce Keyt, Daniel S. Chen, Chan Yoon Y. Cheah, Ching-Fai Pang
Publikováno v:
Blood. 138:132-132
Introduction : IGM-2323 is the first engineered high-affinity, high-avidity bispecific IgM monoclonal antibody TCE to be tested in the clinic. It has 10 binding domains for CD20 and a single binding domain for CD3 and is designed to bind irreversibly
Autor:
Eline van Diest, Froso Karaiskaki, Dennis X. Beringer, Sanne van Dooremalen, Jürgen Kuball, Zsolt Sebestyén, Jan Gumathi Bormin, Lucrezia C D E Gatti, Trudy Straetemans, Inez Johanna, Anna Vyborova, Sabine Heijhuurs, Patricia Hernández López, Mara J T Nicolasen, Angelo D Meringa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Backgroundγ9δ2 T cells hold great promise as cancer therapeutics because of their unique capability of reacting to metabolic changes with tumor cells. However, it has proven very difficult to translate this promise into clinical success.MethodsIn o
Autor:
Shaogang Wang, Xu Ma, Xizhang Wang, M. Pei, Y. Jia, Jianrong Xu, Tao Wang, S. Huang, P. Zhou, C. Zhao
Publikováno v:
Annals of Oncology. 32:S603
Autor:
Ian W. Flinn, Maya Leabman, Ajay K. Gopal, Philippe Armand, Michael S. Gordon, Genevive Hernandez, Daniel S. Chen, Wayne R. Godfrey, Ching-Fai Pang, Bruce Keyt, Iris Sison, Steve Carroll, Elizabeth Budde, Loretta J. Nastoupil
Publikováno v:
Blood. 136:45-46
Introduction : Bispecific antibodies that bridge lymphoma cells to T-cells have shown promise in treating B-cell malignancies. However, existing T cell engaging antibodies are associated with toxicity, especially cytokine release syndrome (CRS), whic
Autor:
Ruth A. Chenault, Alice S. Mims, Christopher R. Cogle, Paul J. Shami, Bret Macpherson, Tara L. Lin, Catherine J. McMahan, Justin M. Watts, Scott Stromatt, Jane A. Gross, Eunice S. Wang, Roland B. Walter, Allison Given Chunyk, Elizabeth H. Cull, Prapti A. Patel
Publikováno v:
Blood. 136:11-12
Introduction Immunotherapy offers the promise of a new paradigm for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). CD123, the IL-3 receptor alpha-chain, represents an attractive target for an